



## **IBA Molecular North America, Inc. to be Acquired by Illinois Health and Science**

**Louvain-la-Neuve – 17 April 2015** - IBA (Ion Beam Applications S.A.) the world's leading provider of proton therapy solutions for the treatment of cancer, announces today that Illinois Health and Science (IHS), a non-profit healthcare system, has signed a definitive agreement with IBA Molecular (IBAM), a joint-venture jointly owned by IBA and SK Capital Partners, to acquire IBA Molecular North America, Inc. (IBAM NA), the US subsidiary of IBA Molecular. The acquisition includes all of IBAM NA's cyclotron sites and its research and development facilities.

The transaction is subject to financing. The terms of the transaction have not been disclosed by parties, but it is not expected to have a significant financial impact on IBA's 2015 P&L at closing, expected in the coming months.

More information can be found in the [IBA Molecular press release](#).

**\*\*\*END\*\*\***

### **About IBA Molecular**

IBA Molecular is a leading developer, manufacturer and distributor of radiopharmaceutical products and supporting services used in molecular imaging with operations throughout Europe, Asia and the U.S. IBA Molecular has a unique product portfolio and pipeline of diagnostic and therapeutic tracers aimed at advancing the development of the global movement towards personalized medicine and making molecular imaging/therapy a major discipline in healthcare. The company also provides educational, technical and marketing support to medical specialists worldwide to help better respond to patient needs. IBA Molecular is jointly owned by SK Capital Partners and IBA (Ion Beam Applications S.A.). For more information, please visit [www.ibamolecular.com](http://www.ibamolecular.com)

### **About Illinois Health and Science**

Illinois Health and Science (IHS) is a non-profit healthcare system that specializes in enhancing patient care by making strategic investments in healthcare related opportunities. Focused on enhancing the span, experience, and quality of human life, IHS is a science and technology based firm, with specific focus on creating patient value. Headquartered in Illinois, IHS is led by senior leaders from healthcare and financial services industries. For more information, please visit [www.ihs Holdings.org](http://www.ihs Holdings.org)

### **About IBA**

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full scale proton therapy centers as well as compact, single room systems.



In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1100 people worldwide, IBA has installed systems across the world, from Europe and the US and to the emerging markets. IBA is listed on the pan-European stock exchange Euronext. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: [www.iba-worldwide.com](http://www.iba-worldwide.com)

### **For further information please contact:**

#### **IBA**

##### **Jean-Marc Bothy**

Chief Financial Officer

Tel: +32 10 47 58 90

##### **Thomas Ralet**

Vice-President Corporate Communication

+32 10 47 58 90

[communication@iba-group.com](mailto:communication@iba-group.com)

#### **For media and investor enquiries:**

##### **Consilium Strategic Communications**

Amber Bielecka, Matthew Neal, Jessica Hodgson and Ivar Milligan

+44 (0)20 3709 5700

[IBA@consilium-comms.com](mailto:IBA@consilium-comms.com)

##### **Rx Communications Group (US)**

Melody Carey

+ 1 917 322 2571

[mcarey@RxIR.com](mailto:mcarey@RxIR.com)